ArticleHealth promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals2026
Mapping Access to Nicotine Vaping Products for Smoking Cessation: Pharmacist Needs and Practice Implications in South-East Melbourne.
Article in Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mapping Access to Nicotine Vaping Products for Smoking Cessation: Pharmacist Needs and Practice Implications in South-East Melbourne.Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn October 2024, nicotine vaping products (NVPs) containing ≤ 20 mg/mL nicotine were reclassified to the Schedule 3 ('pharmacist-only') category, permitting pharmacy-based supply of unregistered therapeutic vapes for smoking cessation in Australia. This regulatory shift expanded pharmacists' roles in tobacco harm reduction, yet their preparedness and capacity to deliver counselling and product supply, specifically related to unregistered therapeutic vapes under the 2024 reforms, remain unclear. In South-East Melbourne, where smoking and vaping rates are high, equitable access to cessation services via community pharmacy is a public health priority. This study examined the availability of therapeutic vapes in pharmacies and explored pharmacists' smoking cessation practices and support needs.
methodsA sequential mixed methods study was conducted across the South East Public Health Unit (SEPHU) catchment in Victoria. It included: (1) an audit of therapeutic vape availability in community pharmacies; (2) a survey of pharmacists' cessation practices, confidence and service provision and (3) qualitative interviews to contextualise findings. Survey and audit data were mapped using Geographic Information System (GIS) tools to examine spatial patterns in NVP availability, socioeconomic status (SES) and smoking and vaping prevalence. Interview transcripts were analysed using Braun and Clarke's 6-step framework for thematic analysis. Data were collected between May and July 2025.
resultsOf 418 community pharmacies audited in the catchment region, 174 (41.6%) reported supplying therapeutic vapes. Seventy (16.7%) pharmacists completed the survey; most (n = 30/32, 93%) dispensed therapeutic vapes fewer than five times weekly. Availability was higher in areas of greater socioeconomic advantage. Interviews revealed barriers to supply including perceptions of limited evidence, low demand and shelf space constraints. Ethical tensions around therapeutic vape provision, commercial pressures influencing supply decisions and systemic barriers to counselling including time constraints and lack of remuneration were also identified.
conclusionsBy mid-2025, therapeutic vapes were available in fewer than half of community pharmacies in South-East Melbourne, with access skewed towards higher socioeconomic status (SES) areas. Pharmacists faced multiple barriers to the provision of nicotine vaping products and cessation counselling, shaped by commercial determinants and systemic constraints. Further research and regional public health action are needed to support equitable, evidence-based cessation care in community pharmacy. SO WHAT: Uneven availability of therapeutic vapes across socioeconomic areas risks reinforcing existing inequities in smoking cessation support. Targeted public health strategies are needed to improve equitable access, strengthen pharmacist capacity and ensure implementation of vaping reforms aligns with broader smoking cessation goals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.